Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Licensing deals
Biotech
Merck pays $588M for bispecific to defend Keytruda’s kingdom
The outlay, plus up to $2.7 billion in milestones, has secured Merck global rights to LaNova Medicines’ PD-1xVEGF bispecific antibody.
Nick Paul Taylor
Nov 14, 2024 7:45am
Novartis pays Schrödinger $150M to form drug discovery pact
Nov 12, 2024 8:55am
GSK pays Flagship biotech $80M for preclinical neuro pact
Nov 12, 2024 6:30am
Ideaya pushes ahead with Biocytogen bispecific ADC bet
Nov 11, 2024 8:50am
VC firm, Chinese biotech launch autoimmune-focused Oblenio Bio
Nov 7, 2024 11:35am
In $285M deal, Novo taps Ascendis to help create monthly GLP-1
Nov 4, 2024 8:43am
